Claudia A. Kistler
Helsinki, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.
Journal: Journal for immunotherapy of cancer
Published: July 27, 2026
Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: December 01, 2025
Dyslipidaemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumours.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 14, 2025
Dyslipidemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumors.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 14, 2025
Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma.
Journal: Immuno-oncology technology
Published: January 13, 2025
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial.
Journal: Journal for immunotherapy of cancer
Published: January 09, 2025
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes.
Journal: Cancer gene therapy
Published: November 27, 2024
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors.
Journal: Journal of experimental & clinical cancer research : CR
Published: September 11, 2024
Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.
Journal: Cell reports. Medicine
Published: August 29, 2024
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.
Journal: Nature communications
Published: May 21, 2024
Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 10, 2023
Gastrointestinal toxicities of immune checkpoint inhibitors: a multicenter retrospective analysis.
Journal: Annals of gastroenterology
Published: May 02, 2020
Last Updated: 09/26/2026